1-2 of 2
Michael Knopp
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Free
Nancy Bartlett, Hongli Li, Michael Knopp, Chad Wright, Heiko Schoder, Lawrence Schwartz, Sharon Castellino, Sarah Rutherford, Andrew Evens, Kelly Davison, Angela Punnett, Margaret Shipp, Brad Kahl, John Leonard, Sonali Smith, Joo Song, Lale Kostakoglu, Kara Kelly, Michael LeBlanc, Jonathan Friedberg, Alex Herrera
Journal: Blood
Blood (2025) 146 (Supplement 1): 1851.
https://doi.org/10.1182/blood-2025-1851
Published: 2025
Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Free
Alex Herrera, Michael Leblanc, Sharon Castellino, Hongli Li, Sarah Rutherford, Andrew Evens, Kelly Davison, Susan Parsons, Sairah Ahmed, Carla Casulo, Nancy Bartlett, Joseph Tuscano, Matthew Mei, Brian Hess, Ryan Jacobs, Boyu Hu, Craig Moskowitz, Christopher Forlenza, Andrew Doan, Adam Lamble, David Hodgson, Anca Prica, Michael Knopp, Tricia Hernandez, Richard Little, Margaret Shipp, Michael Crump, Brad Kahl, John Leonard, Sonali Smith, Joo Song, Kara Kelly, Jonathan Friedberg
Journal: Blood
Blood (2025) 146 (Supplement 1): 151.
https://doi.org/10.1182/blood-2025-151
Published: 2025